➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Moodys
McKinsey
Medtronic
Dow

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR STANDARDIZED MITE DERMATOPHAGOIDES FARINAE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01247259 Efficacy of Sublingual Immunotherapy in Polysensitized Allergic Rhinitis Patients Completed Seoul National University Hospital N/A 2007-11-01 Recently, interest has increased in sublingual immunotherapy (SLIT) for treating allergic rhinitis. It is often suggested that polysensitized patients might not benefit from specific immunotherapy as much as monosensitized patients, although further research on this subject is needed. This study compared the efficacy of SLIT with standardized house dust mite extract in mono- and polysensitized allergic rhinitis patients. Patients who were sensitized to house dust mites and treated with SLIT for house dust mites for at least 1 year between November 2007 and March 2010 were included. The mono-allergen sensitized group (Mgr) was defined as the patients who were sensitized to Dermatophagoides pteronyssinus (Dp) or D. farinae (Df; n = 70). The poly-allergen sensitized group (Pgr) was defined as the patients who were simultaneously sensitized to house dust mites and other allergens (n = 64). A standardized extract of house dust mites was used for immunotherapy. Anti-allergic medication and the total nasal symptom score (TNSS), including rhinorrhea, sneezing, nasal obstruction, and itchy nose, were evaluated before and 1 year after SLIT. This study enrolled 134 patients. The TNSS improved significantly after SLIT in both groups, while the change in the TNSS did not differ significantly between the groups. The anti-allergic medication scores also decreased significantly in both groups, but there was no significant difference between the groups. In polysensitized allergic rhinitis patients, SLIT for Dp/Df gave comparable improvements in both nasal symptoms and rescue medication scores to those in monosensitized patients, regardless of other positive allergens. SLIT for Dp/Df might be considered in polysensitized allergic rhinitis patients.
NCT01529437 Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies Completed Stanford University Phase 1 2005-01-01 This is a study for children and adults who are interested in a new therapy for their allergies to dust mite and timothy grass. The new therapy is called sublingual immunotherapy and the investigators are testing if it is safe and well tolerated.
NCT02269566 Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients Terminated Thermo Fisher Scientific Phase 1 2014-08-01 We will perform double-blinded placebo-controlled randomized clinical trial which evaluates the efficacy and safety of allergen-specific intralymphatic immunotherapy (ILIT) for allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat, and dog that are sensitized and provoke rhinitis-related symptoms in patients with allergic rhinitis.
NCT02269566 Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients Terminated Gachon University Gil Medical Center Phase 1 2014-08-01 We will perform double-blinded placebo-controlled randomized clinical trial which evaluates the efficacy and safety of allergen-specific intralymphatic immunotherapy (ILIT) for allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat, and dog that are sensitized and provoke rhinitis-related symptoms in patients with allergic rhinitis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE

Condition Name

Condition Name for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE
Intervention Trials
Allergic Rhinitis 4
Asthma 3
Allergies 1
Asthma, Allergic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE
Intervention Trials
Rhinitis, Allergic 4
Rhinitis 4
Inflammation 3
Hypersensitivity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE

Trials by Country

Trials by Country for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE
Location Trials
United States 4
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE
Location Trials
North Carolina 3
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE

Clinical Trial Phase

Clinical Trial Phase for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE
Clinical Trial Phase Trials
Phase 1/Phase 2 3
Phase 1 3
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE
Clinical Trial Phase Trials
Enrolling by invitation 2
Completed 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE

Sponsor Name

Sponsor Name for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE
Sponsor Trials
University of North Carolina, Chapel Hill 3
National Heart, Lung, and Blood Institute (NHLBI) 3
Gachon University Gil Medical Center 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for STANDARDIZED MITE DERMATOPHAGOIDES FARINAE
Sponsor Trials
Other 9
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Express Scripts
McKesson
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.